Exelixis vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Exelixis Inc (EXEL)

Q3 202622 Jun – 15 Sep 2026

▲3▼1

Exelixis: Zanza Nears Launch, Cabometyx NET Ramp Lags

Zanzalintinib launch preparation Exelixis is preparing to launch zanzalintinib in third-line colorectal cancer after the FDA accepted its application with a December 3, 2026 decision date. The company sees a $1.5 billion market opportunity, giving EXEL a new growth driver beyond its flagship Cabometyx.
This is the main new pipeline catalyst that could add a second major revenue stream.
Cabometyx NET ramp slower than expected Exelixis lowered its 2026 revenue guidance by $50 million because the neuroendocrine tumor launch of Cabometyx is ramping more slowly than planned. The company says the gap is temporary, but it means near-term sales will be lower than hoped.
This is the key negative that explains why guidance was cut and tempers the growth story.
Strong Q2 results and new buyback Exelixis beat second-quarter earnings estimates and announced a new $750 million share repurchase program after completing the previous one. The buyback can support the stock price by reducing the number of shares outstanding.
This shows financial strength and a concrete action that can lift the stock price.
Cabometyx franchise remains solid Cabometyx sales grew about 10% year-over-year, and Exelixis still aims for a $3 billion franchise. It holds roughly 47% of new-patient share in neuroendocrine tumors, showing the core business is still expanding even if the launch is slower than expected.
This provides a counterweight to the guidance cut and shows the base business is healthy.

August 202622 Jun – 15 Sep 2026

▲3▼1

Exelixis: Zanza Nears Launch, Cabometyx NET Ramp Lags

Zanzalintinib launch preparation Exelixis is preparing to launch zanzalintinib in third-line colorectal cancer after the FDA accepted its application with a December 3, 2026 decision date. The company sees a $1.5 billion market opportunity, giving EXEL a new growth driver beyond its flagship Cabometyx.
This is the main new pipeline catalyst that could add a second major revenue stream.
Cabometyx NET ramp slower than expected Exelixis lowered its 2026 revenue guidance by $50 million because the neuroendocrine tumor launch of Cabometyx is ramping more slowly than planned. The company says the gap is temporary, but it means near-term sales will be lower than hoped.
This is the key negative that explains why guidance was cut and tempers the growth story.
Strong Q2 results and new buyback Exelixis beat second-quarter earnings estimates and announced a new $750 million share repurchase program after completing the previous one. The buyback can support the stock price by reducing the number of shares outstanding.
This shows financial strength and a concrete action that can lift the stock price.
Cabometyx franchise remains solid Cabometyx sales grew about 10% year-over-year, and Exelixis still aims for a $3 billion franchise. It holds roughly 47% of new-patient share in neuroendocrine tumors, showing the core business is still expanding even if the launch is slower than expected.
This provides a counterweight to the guidance cut and shows the base business is healthy.

Latest22 Jun – 15 Sep 2026

▲3▼1

Exelixis: Zanza Nears Launch, Cabometyx NET Ramp Lags

Zanzalintinib launch preparation Exelixis is preparing to launch zanzalintinib in third-line colorectal cancer after the FDA accepted its application with a December 3, 2026 decision date. The company sees a $1.5 billion market opportunity, giving EXEL a new growth driver beyond its flagship Cabometyx.
This is the main new pipeline catalyst that could add a second major revenue stream.
Cabometyx NET ramp slower than expected Exelixis lowered its 2026 revenue guidance by $50 million because the neuroendocrine tumor launch of Cabometyx is ramping more slowly than planned. The company says the gap is temporary, but it means near-term sales will be lower than hoped.
This is the key negative that explains why guidance was cut and tempers the growth story.
Strong Q2 results and new buyback Exelixis beat second-quarter earnings estimates and announced a new $750 million share repurchase program after completing the previous one. The buyback can support the stock price by reducing the number of shares outstanding.
This shows financial strength and a concrete action that can lift the stock price.
Cabometyx franchise remains solid Cabometyx sales grew about 10% year-over-year, and Exelixis still aims for a $3 billion franchise. It holds roughly 47% of new-patient share in neuroendocrine tumors, showing the core business is still expanding even if the launch is slower than expected.
This provides a counterweight to the guidance cut and shows the base business is healthy.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.